Skip to main content

Table 1 Clinical characteristics of patients

From: Clinical significance of tumor-infiltrating lymphocytes investigated using routine H&E slides in small cell lung cancer

  Total sTIL+ sTIL− p  
Gender     0.343  
Male 145 69 76   
Female 14 8 6   
Median age (year, rang) 59.5 (24–84) 58.8 (38–84) 60.0 (24–77) 0.624  
Clinical T stage     0.250  
T1 16 10 6   
T2 39 16 23   
T3 52 21 31   
T4 52 30 22   
Mean Dmax-T (cm) 5.613 5.56 5.66 0.672  
Clinical N stage     0.520  
0 13 6 7   
1 6 4 2   
2 74 33 41   
3 66 34 32   
Clinical M stage     0.270 M0 versus M1
M0 90 46 44   
M1 69 31 38   
EM only 51 24 27 0.587 EM versus BM
BM only 8 4 4   
EM and BM 10 3 7   
Clinical TNM stage     0.301  
I 1 1 0   
II 4 1 3   
III 86 44 42   
IV 68 31 37   
Regimen of CT     0.539  
EP 107 50 57   
EC 34 15 19   
EN 6 4 2   
IP 6 4 2   
Others 6 4 2   
Median cycles of CT (range) 4.7 (1–8) 4.7 (1–8) 4.7 (1–7) 0.870  
TRT     0.173  
No 77 33 44   
Yes 82 44 38   
Median dose of TRT (cGy, range) 5599 (3600–6900) 5595 (40,006–900) 5604 (3600–6400) 0.682  
PCI     0.414  
No 151 72 79   
Yes 8 5 3   
  1. BM, brain metastasis; CT, chemotherapy; Dmax-T, greatest dimension of tumor; EP, etoposide with cisplatin; EC, etoposide with carboplatin; EM, extracranial metastasis; EN, etoposide with nidaplatin; IP, irinotecan with cisplatin; TRT, thoracic radiotherapy